Cardiology
Nifekalant renders electrical defibrillation more successful
Published in Heart Disease Weekly, September 4th, 2005
According to researchers in Japan, "In severely ill patients, the development of atrial fibrillation (AF) may provoke lethal hemodynamic instability requiring immediate electrical defibrillation, which often is unsuccessful. Using the novel potassium channel blocking agent nifekalant, we prospectively assessed the hypothesis that class III antiarrhythmic drugs facilitate electrical cardioversion and suppress the immediate recurrence of hemodynamically deleterious AF."
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Heart Disease Weekly
Source: Heart Disease Weekly (2005-09-04)
More Articles from Heart Disease Weekly
- Cardiac Transplantation
Caspase-3 inhibition prevents graft coronary artery disease in transplantation - Cardiac Transplantation
Changes in ejection fraction or volume in transplanted hearts are abnormal - Medical Devices
Technique may reduce morbidity of open-chest transmyocardial revascularization - Myocardial Infarction
Aqueous oxygen prevents LV remodeling, preserves LV ejection fraction - Ablation
Specially equipped electrodes may prevent burns during ablation - Acute Pulmonary Embolism
Company gets approval for Cleactor Inj in Japan - More from this issue of Heart Disease Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
